[Relationship between sevelamer HCl and vascular calcification].
The Kidney Disease Outcomes Quality Initiative (K/DOQI) issued "Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease", in which it is recommended that the level of intact parathyroid hormone (i-PTH) should be kept at 150 - 300 pg/mL, the serum phosphorus (P) level at 3.5 - 5.5 mg/dL, and the serum calcium (Ca) level within the normal range of laboratory values (8.4 - 9.5 mg/mL, as close to the lower limit as possible). In developing these guidelines, the K/DOQI apparently considered the recently established fact that control of Ca, P and PTH influences not only the development of bone lesions but also patient prognostic factors such as arteriosclerosis, ectopic calcification, and cardiovascular complications, as well as the development of various vitamin D products and analogues and new P adsorbents. The Japanese guidelines also emphasize the control of P and Ca, rather than PTH. Therefore Phosphorus control is a primary goal in the care of patients with end-stage renal disease. We inspect the relationship between Vascular calcification and Sevelamer HCl, a non-aluminium, non-calcium, non-absorbed phosphate binder.
Uemura
Katsuya
K
Uemura Circulation Clinic.
Kakuta
Takatoshi
T
Saito
Akira
A
D001851:Bone Diseases, Metabolic / Q000209:etiology / Q000517:prevention & control; D002114:Calcinosis / Q000209:etiology* / Q000517:prevention & control*; D002614:Chelating Agents / Q000008:administration & dosage*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D010758:Phosphorus / Q000097:blood; D011073:Polyamines / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D006435:Renal Dialysis / Q000009:adverse effects; D000069603:Sevelamer; D014652:Vascular Diseases / Q000209:etiology* / Q000517:prevention & control*
D002614:Chelating Agents; D011073:Polyamines; D010758:Phosphorus; D000069603:Sevelamer